SITC Meeting

TGF-BR1 Inhibitor Shows Early Activity and Tolerability in Advanced Cancers

November 26, 2018

Treatment of patients with advanced or metastatic cancers with the transforming growth factor-β receptor type 1 inhibitor LY3200882 demonstrated a tolerable safety profile and early signs of efficacy, according to the results from a first-in-human, dose-escalation phase I trial presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer.

CSCC Lesions Found in Few Patients Treated With PD-1/PD-L1 Checkpoint Inhibition

November 13, 2018

An analysis of patients who presented to MD Anderson Cancer Center’s dermatology clinic following treatment with anti–PD-1/PD-L1 treatment suggests a potential association between the development of cutaneous squamous cell carcinoma lesions and PD-1/PD-L1 checkpoint inhibition.

Two Rapid-Fire Abstracts Break Down Biomarkers of Response and Resistance

November 12, 2018

An analysis of immunologic biomarkers in a phase II trial of patients with advanced colorectal cancer treated with chemotherapy and PD-1 checkpoint inhibition identified several factors associated with a patient’s beneficial response to the chemo-immunotherapy regimen, according to findings presented during the 33rd Annual Meeting of the Society for Immunotherapy of Cancer.

Combination Therapy With Mogamulizumab Demonstrates Tolerable and Manageable AEs

November 12, 2018

Results from a two-part, phase I dose-escalation and -expansion trial involving mogamulizumab in combination with durvalumab or tremelimumab for the treatment of patients with advanced solid tumors demonstrated mild-to-moderate adverse events that were tolerable and manageable, according to Dmitriy Zamarin, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, during his presentation at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer.

Phase I Study Considers Potential for Personalized Immunotherapy in Glioblastoma

November 11, 2018

A peptide-based personalized vaccine demonstrated encouraging signals of efficacy and was well tolerated in patients with newly diagnosed glioblastoma, according to the results of the phase I GAPVAC-101 trial.

Augmenting T Cell Immunity in Cold Tumors

November 11, 2018

Stephanie K. Dougan, MD, assistant professor, Dana-Farber Cancer Institute and Harvard Medical School, discusses the idea of augmenting T cell immunity in tumors that are poorly immunogenic, such as pancreatic cancer.

CD8-Tracer Is Safe, Shows Biodistribution of T Cells in Tumors

November 10, 2018

The CD8-tracer 89Zr-IAB22M2C, an anti-CD8 radiolabeled minibody, was found to be safe, well-tolerated, and demonstrated whole-body biodistribution of CD8-positive T cells in tumors and reference tissues, according to first-in-human results presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer.

Computer Analysis Determines Best Practices for Use of Tumor Mutational Burden in Patient Care

November 10, 2018

In an effort to determine best practices and ensure consistent clinical interpretation of tumor mutational burden assessment for patients with cancer, a group of diagnostic test partners conducted an in silico analysis and found that panel-derived TMB strongly correlated with whole-exome sequencing data provided from The Cancer Genome Atlas.

Immunologic Biomarker Findings for mFOLFOX6 and Pembrolizumab in CRC

November 10, 2018

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses immunologic biomarker findings in a study of mFOLFOX6 plus pembrolizumab (Keytruda) in colorectal cancer.

Preliminary Findings From the NCI-MATCH Trial for Mismatch Repair-Deficient Cancers

November 12, 2017

Nilofer Azad, MD, associate professor, Johns Hopkins University, discusses preliminary results from the NCI-Match trial for nivolumab (Opdivo) in patients with mismatch repair-deficient cancers The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.